Cart
sales@molnova.com
Ragifilimab
CAS No. 2207590-51-8
Ragifilimab( —— )
Catalog No. M36831 CAS No. 2207590-51-8
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 211 | Get Quote |
|
| 5MG | 330 | Get Quote |
|
| 10MG | 543 | Get Quote |
|
| 25MG | 845 | Get Quote |
|
| 50MG | 1150 | Get Quote |
|
| 100MG | 1521 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRagifilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionRagifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.
-
DescriptionRagifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2207590-51-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hernandez-Guerrero T, et al: Not Ready for Prime Time. Clin Cancer Res. 2022 Sep 15;28(18):3905-3907.?
molnova catalog
related products
-
Atibuclimab
Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region.
-
MALTOTETRAOSE
MALTOTETRAOSE are potent inhibitors of TNF-α-induced intercellular adhesion molecule-1 (ICAM-1) expression maltotetraose may be beneficial in the suppression of early atherosclerosis development.
-
Zigakibart
Zigakibart (BION-1301) is a humanized monoclonal antibody targeting TNFSF13 with anti-inflammatory activity for the study of immunoglobulin A nephropathy (IgAN).
